The
beauty potential of our skin
is locked deep within our cells, in their
genetic makeup
. Fibroblasts are responsible for synthesizing vital com-
ponents of the dermis, and are therefore essential contributors to the
youthful appearance of our skin.
Our lifestyles can change this potential and accelerate the aging pro-
cess through an
epigenetic mechanism
. While the fibroblasts’ genetic
code does not directly change under
negative environmental influ-
ences
, certain parts of their DNA are shut down when
a specific en-
zyme is activated (DNMT3a)
. As a result, several gene sequences in
the fibroblasts are no longer read out, protein production is halted, and
skin cell vitality declines.
With the discovery of DERMAGENIST™, a way has been found to protect
skin against this undesired epigenetic gene silencing, by inhibiting
DN-
MT3a enzyme activity
(see Fig. 1). The result is a
reactivation of LOXL
genes
(see Fig. 2). The LOXL enzyme plays an important role in the
func-
tionalization of connective tissue fibres
.
Fig 1: DERMAGENIST™ inhibits DNA methylation by reducing acti-
vity of the enzyme DNMT3a
Fig 2: DERMAGENIST™ reactivates LOXL gene transcription by 66%.
The gene is reactivated and can be “read” once again
DERMAGENIST™ furthermore increases
pro-collagen synthesis
and sti-
mulates key proteins that play an important role in the
functionalizati-
on of connective tissue
. Extracellular spaces are refilled with a
functio-
nal, three-dimensional collagen network
(see Fig. 3).
Untreated control
Vitamin C DERMAGENIST
TM
0.04%
Fig 3: DERMAGENIST™ fills extracellular space with a 3D collagen
network (grey marking)
Another important way in which DERMAGENIST™ improves skin elasti-
city is by stimulating the synthesis of actin, a key structural protein that
reinforces the cytoskeleton of fibroblasts
. The cells are revitalized and
become more contractile.
Two clinical trials have been performed. Twice daily over a period of 56
days, 30 women aged between 40 and 65 treated one half of the face
with 0.4% DERMAGENIST™ and the other half of the face with a placebo
formulation. The skin density was determined using high-resolution
ultrasonic measurement. An
18% increase in skin density
in the
cheek area was observed after 56 days. Furthermore, skin firmness was
determined by a score system. There was an observed
improvement in
skin firmness of 10%
after 56 days and
15%
after 84 days.
DERMAGENIST™ is extracted from marjoram leaves. A special method
ensures the active ingredient is rich in polyphenols, vicenin and luteolin-
7-0-glucuronide.
DERMAGENIST
TM
:
• Protects against epigenetic modification of DNA; reduces gene
silencing
• Reactivates the gene expression of extracellular matrix components
• Vitalizes fibroblasts
• Improves the neo-collagen network
Skin care applications:
• Anti-aging
• “Epi-protector”
• “Cell tonic” technology
• Tightness
• Improved skin density
DERMAGENIST™ PW BC10004
INCI:
Maltodextrin (and) Origanum Majorana Leaf Extract
Appearance:
White to beige powder
Preservatives:
None
Application concentration:
0.2–0.4%
DERMAGENIST™
is a trademark of BASF
2
120%
100%
80%
60%
40%
20%
0%
–30%
Untreated
Control
DERMAGENIST
TM
0.065%
DNMT 3a methylation: luciferase activity
(%relative to untreated)
student test
* p < 0.05
** p < 0.01
*
2.5
2
1.5
1
0.5
0
+66%
Untreated
Control
DERMAGENIST
TM
0.065%
LOXL 1 mRNA level (vs untreated control)
n = 3
Mean ± SEM
student test versus
untreated control
* p < 0.05
*
D E R M A G E N I S T ™
Revitalizes the skin’s beauty potential
